drugset
drugset / Trial / NCT05935748

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NCT05935748 ↗

Phase 2 Terminated 18 enrolled NiKang Therapeutics, Inc. Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.

Timeline

Start
2023-07-28
Primary completion
2025-06-30
Completion
2025-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject NKT2152 Unknown — Oral
Subject Palbociclib Small molecule — —

Indications

clear cell renal carcinoma